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Polymeric nanomaterials have the potential to improve upon present chemotherapy delivery methods. They successfully reduce
side effects while increasing dosage, increase residence time in the body, offer a sustained and tunable release, and have the ability
to deliver multiple drugs in one carrier. However, traditional nanomaterial formulations have not produced highly therapeutic
formulations to date due to their passive delivery methods and lack of rapid drug release at their intended site. In this paper,
we have focused on a few “smart” technologies that further enhance the benefits of typical nanomaterials. Temperature and pH-
responsive drug delivery devices were reviewed as methods for triggering release of encapsulating drugs, while aptamer and ligand
conjugation were discussed as methods for targeted and intracellular delivery, with emphases on in vitro and in vivo works for each
method.
1. Introduction
A major obstacle for chemotherapy is the inability to deliver
adequate doses of drugs to the affected areas in the body.
Systemic toxicity of these drugs limits their dose, while rapid
clearance from circulation requires large doses in order to be
effective. Doxorubicin, for instance, has a five to ten minute
half life in the plasma [1].
Polymeric nanomaterials offer a promising solution by
encapsulating chemotherapy drugs, and have been shown
to reduce toxicity by providing a protective housing for the
drug that limits its interaction with healthy cells [2–5]. As
a result, the pharmacokinetic properties of the drug are
based on the pharmacokinetic properties of the particle, as
long as the drug can stay entrapped with the carrier until
release is desired [6]. The potential benefits of such delivery
devices also include controlled and long-term release rates,
prolonged bioactivity, reduced side effects, increased patient
compliance due to decreased administration frequency, and
the ability to codeliver multiple drugs with synergistic effects
to the same site [7–9].
Delivery devices made from erodible polymers are
an attractive option over nonerodible ones because they
degrade and gradually disappear after delivery [10]. Of these
polymers, poly(ε-caprolactone), poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and their copolymers have been
among the most extensively researched due to their bio-
compatibility, biodegradability, and regulatory approval [11–
15]. For an anticancer drug carrier to prove effective,
prolonged circulation times and controlled drug release
at the tumor site are required [16, 17]. Various works
have already been done to improve particle circulation
time by limiting renal secretion and hindering uptake by
the reticuloendothelial system (RES) [18–22]. This is often
accomplished by pairing poly(ethylene glycol) (PEG) with
the polymer of the nanoparticle. PEG has been shown to
inhibit the binding of plasma proteins to the surface of
polymeric drug carriers, preventing their recognition by the
RES. This imparts “stealth” properties to the delivery device,
increasing its systemic circulation time significantly [23].
Passive targeting is created because the size of the
polymeric systems and their increased residence time make
them suitable carriers to take advantage of the enhanced
permeability and retention (EPR) effect in tumors [6, 24,
25]. The EPR effect is described as hyperpermeable tumor
vessels that allow for the extravasation of circulating macro-
molecules, such as polymeric nanomaterials, that, combined
with the lack of a lymphatic drainage system, results in their
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gradual accumulation [26]. While this results in localized
delivery gradually over time, there still remains the need
for drugs that act intracellularly to release and permeate
the cell walls. In addition, it has been shown that slow and
passive drug release from drug-carrying particles reduces
their effectiveness in cancer treatment [27]. Overall, passive
polymer drug carriers have not demonstrated increased
therapeutic efficacy due to lack of intercellular and localized,
rapid drug delivery [28–30].
Current research has thus focused on advancing these
polymer vehicles with “smart” technologies that are respon-
sive to environmental stimuli. These can be separated into
two categories: (1) site-targeting, where particles actively
search for and attach themselves to specific and diseased
cells by the use of molecules such as ligands, antibodies,
and aptamers; (2) site-triggering, where chemical or physical
changes in the environment trigger the rapid release of
the drug payload. This review focuses on a few selected
“smart” technologies in each category: ligand and aptamer
site-targeting particles, and pH and temperature-responsive
particles.
2. Smart Nanomaterials
2.1. Site-Targeted Nanomaterials
2.1.1. Ligands. Attaching targeting ligands to the particle
surface can take advantage of the overexpression of various
receptors on tumor cell surfaces [31, 32]. Coupled with
the passive accumulation at tumor sights caused by the
EPR effect, targeted particles can increase the interaction
time between particles and the tumor cell and increase the
likelihood of the particles being taken up by the tumor cells
via endocytosis [33].
Targeted delivery takes advantage of differences in the
expression of cell surface receptors between healthy and
tumor cells. For example, folate receptors are known to
be vastly overexpressed in several human tumors [34–36].
Attaching folate to the outer shell of particles can create a
targeted drug delivery carrier. Folate conjugation has shown
success at creating targeted anticancer agents that can avoid
nonspecific attacks on normal tissue and increase cellular
uptake within target cells [31–33, 37, 38].
PEG is commonly associated with the surfaces of micelle-
like particles and liposomes to increase particle circulation.
By coupling ligands to polyethylene glycol (PEG), a targeted
particle can be created where the ligand is expressed on
the particle surface. Combining the benefits of prolonged
particle circulation with the benefits of delaying drug release,
an ideal system exists for targeted delivery [33, 39–45].
The increased residence time increases the likelihood of
interaction between receptor and target for targeted delivery.
Yoo et al. developed folate-conjugated PEG-co-poly
(lactic-co-glycolic acid) (PEG-PLGA) micelles loaded with
the anti-cancer drug doxorubicin that expressed folate on the
micelle surface [33]. Studies indicated increased cytotoxicity
and decreased tumor growth for folate conjugated micelles
as opposed to nontargeted micelles and free DOX [33].
Targeted particles also showed increased cellular uptake [33].
2.1.2. Aptamers. Aptamers are DNA and RNA sequences
that recognize specific target analytes [46]. Aptamers can be
selected to bind with high specificity and affinity to a wide
range of molecules such as organic dyes, amino acids, bio-
logical cofactors, antibiotics, peptides, proteins, and whole
cells [47]. Aptamers are often compared to antibodies for
their affinity to select molecules, but despite their similarities,
offer several important advantages: aptamers can be easily
synthesized in vitro without the need for an induced immune
response from animals [48], which makes them able to target
nonimmunogenic molecules; the aptamer synthesis process,
SELEX, can be carried out in nonphysiological settings
[49]; they are more stable and can be obtained at a lower
cost [50].
Since the targeted molecule can be uniquely associated
with a particular disease, early research into aptamers has
concentrated on early-stage disease diagnosis, particularly in
cancer. Common cancer diagnostic methods involve somatic
or visual techniques, such as self-examinations and localized
X-rays. A major disadvantage of these methods is that they
do not lead to diagnoses until advanced stages in the disease,
a factor in cancers high death rates [51, 52]. However, cancer
is a genetic disease, and aptamers provide a way for screening
at the molecular level using selective cell binding [53].
Cancer-detecting assays using fluorescent imaging that
are currently being developed utilize aptamers conjugated
with dye-doped silica nanoparticles. These fluorescent
nanoparticles are favored over direct dye conjugation due
to their signal amplification and ability to immobilize
biomolecules [54–56]. These particles have often combined
with magnetic particles, which allows for convenient separa-
tion of bound cells, to make two-part aptamer-based assays
[53, 57, 58]. Gold nanoparticles, which are ideal contrasting
agents, have been conjugated with cancer-targeting aptamers
to successfully create assays for detecting prostate and breast
cancer cells [59, 60].
The ability of aptamers to bind directly with diseased
cells has gained them recognition in site-specific drug
delivery research. In particular, systems utilizing polymeric
nanovehicle and aptamer conjugates are believed to create
devices that can deliver high drug doses to diseased cells in a
controlled fashion with minimal toxicity to healthy cells.
In vitro studies involving these systems often utilize
the A10 2′-fluoropyrimidine RNA aptamer, which targets
the prostate-specific membrane antigen (PSMA) found on
the LNCaP cell line. This allows for comparison with
control groups tested against PC3 cells, another prostate-
cancer cell line that does not display the PSMA antigen,
to prove that the drug carriers only have affinity for cells
expressing the targeted antigen [61–63]. Using fluorescent
imaging, this comparison was able to establish that drug
vehicles conjugated with the PSMA-targeting aptamer were
internalized by cells via receptor-mediated endocytosis [64].
PEG-PLGA nanoparticles carrying the chemotherapy drug
docetaxel and targeting PSMA cells in vivo have produced
dramatic reduction in tumor sizes in mice compared to free
docetaxel and non-targeted particles [61]. The increase in
cancer cell toxicity was credited to a combination of the
intracellular delivery of the drug, increased retention time,
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and reduced circulation clearance at the tumor site due to
high-affinity binding with the antigen.
Polymeric micelles have proven to increase the overall
affinity of aptamers that exhibit ones considered too low for
drug-aptamer delivery systems [65]. They do this by taking
advantage of multivalent binding effects, where multiple
aptamers on the micelle surface link with the cell-surface
antigens to produce an overall stronger bond. This allows for
the targeting of unique cellular antigens that would otherwise
be considered unsuitable for drug-aptamer conjugates.
Polymeric nanocarriers provide the benefit of being able
to carry multiple drugs in the same vehicle. This, combined
with aptamer targeting, can be used to selectively deliver
dual-drug payloads to cancerous cells. Due to their different
mechanisms of action, the drugs may provide additive or
synergistic effects that can allow for lower doses, and reduce
side effects [66, 67]. More importantly, this is thought
to combat drug resistance, a major problem associated
with cancer drug treatment [68]. Packaging the drugs in a
nanocarrier, as opposed to a simple mixture, allows for their
simultaneous delivery on a cell-by-cell basis, which has been
proven to be more effective [69–71].
This can even be used to combine drugs with dif-
ferent water solubility properties, as was accomplished by
Zhang et al. using PEG-PLGA [9]. In systems where the
aptamer binding initiates endocytosis, such as with A10
RNA aptamer, combinations of drugs and genes that require
delivery to intracellular compartments to properly function
experience greater benefits [72]. This approach has been
used successfully in aptamer-gene conjugates [73, 74], and
is beginning to see promise in aptamer-nanoparticle conju-
gates. Polyethyleneimine-grafted-PEG (PEI-PEG) nanopar-
ticles carrying doxorubicin and the hairpin shRNA, which
suppresses the antiapoptotic gene Bc1-xl, produced signifi-
cantly lower cell viability and enhanced therapeutic efficacy
compared to single drug-loaded nanoparticle aptamer sys-
tems and free drug mixtures [75].
2.2. Site-triggered Nanomaterials
2.2.1. pH-Responsive Nanomaterials. One method to pro-
mote drug release at the tumor sight is by taking advantage
of the lower pH of the tumor’s microenvironment. Mildly
acidic conditions exist in tumor and inflammatory tissues
(pH 6.8) and in endosomes (pH 5-6) in comparison to
the more neutral physiological condition (pH 7.4) [76,
77]. The ability of nanoparticles to accumulate in solid
tumors has been shown by the enhanced permeation and
retention (EPR) effect [6, 24, 25, 78]. In addition, it has
also been demonstrated that nanoparticles can be taken
up within cancer cells through a process called endocytosis
[79, 80]. Many anticancer drugs, such as doxorubicin, work
by inhibiting cell replication. Thus, for anticancer drugs to be
effective, they must interact with intracellular components.
If particles can gain access to the intracellular components
through endocytosis, then it seems logical that the particle
deliver its payload of anticancer drugs once inside the cell.
Once the particle is taken up via endocytosis, the endocytic
vesicles ultimately change to late endosomes and then to
lysosomes in which the proton concentration is 100 times
higher (pH 5.0) than the physiological condition (pH 7.4)
[76]. Micelle forming polymer-drug conjugates and drug
loaded liposomes provide the potential for drug release
within a lower pH environment. Drug release from micelles
can be targeted to these acidic environments by conjugating
the polymer to the drug with an acid-cleavable linkage.
Release can be targeted to acidic conditions in liposomes
by causing destabilization of the liposome shell under acidic
conditions.
Nanomaterials such as liposomes and micelles are exam-
ples of particles that can accumulate in solid tumors as
a result of the EPR effect [3, 9–11]. Micelles consist of a
hydrophobic core and a hydrophilic corona or shell and
are well suited to entrap and solubilize hydrophobic drugs
within their core. Because some of the most commonly
used cancer drugs are hydrophobic, micelles have gained
widespread use for the delivery of cancer therapeutics [39,
41, 42, 45, 80–83]. Liposomes typically involve a bimolec-
ular phospholipid membrane that encloses an aqueous
compartment. Because liposomes contain a phospholipid
membrane they can entrap hydrophobic drugs, but they
can also encapsulate various hydrophilic drugs such as
peptides, proteins, and nucleic acids within their aqueous
compartment [84, 85]. Previous work has been done to
increase liposome stability by increasing circulation time and
by preventing drug leakage until the target is reached [86–
88]. Micelle like particles and liposomes with pH sensitivity
have shown great promise as delivery vehicles for anticancer
drugs, DNA, RNA, proteins, and peptides [76, 82, 89–98].
In order for micelles to take on pH responsibilities, the
drug is typically conjugated to the polymer that makes up
the core of the micelle by an acid cleavable linkage. The
creation of a polymer-drug conjugation is referred to as a
polymeric prodrug and allows the drug to remain inactive
until cleavage from the polymer carrier. When used in
the formation of micelles, polymeric prodrugs can control
release by chemically attaching the drug within the core of
the micelle or by increasing the thermodynamic stability of
the micelle in order to delay micelle degradation [39, 99].
In order to prolong drug release, an active substance can
be linked to a polymeric molecule via a covalent bond
which is naturally hydrolyzed in vivo [100–102]. For pH-
responsiveness of polymeric prodrug micelles, the linkage
between drug and polymer is more readily hydrolyzed at a
lower pH.
If taken up via endocytosis, drug association with a
polymer carrier can help avoid the multidrug resistance
(MDR) effect (i.e. recycling of chemotherapy drugs). Drug
association with a polymer carrier, either through conjuga-
tion or entrapment within the micelle core, can help limit
free drug being outfluxed from the cancer cell through the
p-glycoprotein pump.
Various works have been done involving the conjugation
of the anti-cancer drug doxorubicin (DOX) to the hydropho-
bic core forming polymer of the micelle [82, 89, 93, 94].
The conjugation of drug to polymer was performed via a
hydrazone linkage and ultimately resulted in enhanced DOX
accumulation and cytotoxicity within tumor cells as opposed
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to free DOX. One of the more promising aspects for this type
of pH-responsive release is the ability of the DOX-conjugated
micelles to circumvent the multi-drug resistant effect once
taken up by endocytosis [82].
One of the main disadvantages of conjugating the
drug to the polymer to get pH responsiveness is the need
to maintain drug bioactivity throughout the conjugation
scheme. Liposomes that are pH responsive overcome this
barrier because the shell of the liposomes is what can be
tailored to exhibit pH effects. Because of previous work to
increase liposome stability and circulation, the liposome can
circulate long enough to passively reach the target sight (EPR
effect), and the drug can stay associated with the liposome
until the proper pH environment is reached [85–88, 91].
In order for liposomes to deliver their payload at the
intracellular layer, the liposomes must first be taken up
by endocytosis. Once taken up, the liposomes need to
destabilize at the lower endosomal pH. This destabilization
can allow the liposome to break down and deliver its contents
into the cell cytoplasm. Modification by the inclusion of
lipids with pH sensitivity can give the liposome “fusogenic”
properties[91]. The term fusogenic refers to the ability of
liposomes to destabilize at the lower endosomal pH and
“fuse” with the endosomal bilayer to allow for access to
the cell cytoplasm. This first became a desired intracellular
release mechanism by the observation that certain viruses
take advantage of the endosomal acidification to infect
cells[91]. Acidic environments within the body also occur
at tumors, inflamed or infected tissue, where pH sensitive
delivery may also be desirable.
Themost common pH-sensitive liposomes are composed
of phosphatidylethanolamine (PE) as the primary bilayer
component combined with compounds that are stable at a
neutral pH, but unstable under acidic conditions [91]. Alter-
ing pH sensitivity is typically done by including pH-sensitive
lipids, synthetic peptides/proteins, or pH-sensitive polymers
within the lipid bilayer or the liposome aqueous com-
partment [91, 103–108]. With PE liposomes destabilization
occurs by intercalation of amphiphilic molecules that contain
a protonatable acidic group (i.e. a carboxylic group) that
becomes protonated under acidic conditions and causes the
PE molecule to revert to an inverted and unstable hexagonal
phase [91, 109, 110]. Some of the most effective molecules
included within the bilayer that induce pH sensitivity and
ultimately, increase drug delivery to the cytoplasm, consist of
combinations of dioleoylphosphatidylethanolamine (DOPE)
and cholesteryl hemisuccinate (CHEMs) [91, 111, 112].
2.2.2. Thermoresponsive. Hyperthermia has been investi-
gated as a method for triggered drug release to targeted areas
in thermoresponsive liposomes. Here, in vivo temperatures
are achieved through either older andmore general methods,
such as warmed baths or perfusates [113], or through more
advances and localized methods, requiring ultrasonic and
microwave units [114, 115]. Since most mammalian cells
begin to show damage at 42◦C [116], hyperthermia is defined
as temperatures between this and physiological temperature
(37◦C). When the liposomes pass through the area with
increased temperature, they release their encapsulated drugs.
In addition to localized drug release, hyperthermia
offers other indirect benefits, such as increased microvessel
permeability in tumors, which causes more liposomes to
accumulate at the intended site [117, 118] while healthy
microvessels are not significantly altered [119]; increased
cell permeability, which allows the released drugs to diffuse
through the cell walls more easily [120]; and increased
sensitivity to thermal injury compared to healthy cells [121].
To take advantage of this triggering mechanism, lipo-
somes must have a liquid-crystalline transition temperature
(Tc) within the accepted temperature range. Upon reaching
this temperature, they become highly permeable to their
water-soluble contents, causing hydrophilic drugs to release
in the intended location [122, 123]. Tc is a material property
of the liposome polymer and is primarily determined by
the length of its fatty acid chains [124]. This allows for
the addition of other polymers to the liposome, notably
polyethylene glycol (PEG), to increase the retention time
and stability [125] and alter the release kinetics [126, 127],
without significantly changing its transition temperature. To
achieve a desirableTc, it is possible to combine polymers with
different transition temperatures in ratios that result in one
in the hyperthermic range [128].
In order for a thermosensitive liposome to be considered
for a drug-delivery device, it must be stable in plasma
circulation, release minimal amount of drug at physiolog-
ical temperatures, and then release its payload quickly in
hyperthermia conditions. Common phospholipids include
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and
1,2-dipalmitoyl-sn-glycero-3-phosphoglyceroglycerol (DPP-
GOG), often in combination and with varying amounts of
PEG [27, 113, 129–131].
In vivo experimentation has proven promising for
these thermo-sensitive devices. The chemotherapy drug
carboxyfluorescein (CF) produced a sixfold bioavailability
increase in cancerous hamsters when packaged in a thermo-
sensitive liposome under hyperthermia compared to free
CF [131]. Similar nanovehicles carrying DOX successfully
eliminated tumors in six out of nine cancerous mice after 60
days [132]. In a phase I clinical trial, temperature-sensitive
liposomes carrying DOX were given to dogs with solid
tumors in conjunction with localized hyperthermia. The
study reported a 17-fold decrease in drug clearance rate when
using the liposomes compared to the free drug, resulting in a
higher bioavailability [133].
Alternatively, copolymers have been designed that have
a different thermo-sensitive property, called the cloud point
(CP), which changes over time, eliminating the need for
hyperthermic conditions. Above the CP, the co-polymer
precipitates out of solution and freely forms micelles that can
encapsulate their drug; below the CP, the polymer dissolves
into solution, causing the micelle to destabilize and release
its payload [134]. Thus, these co-polymers are designed to
begin with a CP that is below ambient conditions so that a
drug vehicle can be made, and then end with a CP that is
above physiological temperature after the micelles have been
delivered to the target cells [135].
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This has been achieved through the use of a novel
class of hydrophobic lactate-containing polymers, notably
poly(N-(2-hydroxypropyl) methacrylamide oligolactates)
(pHPMAm-Lacn) and poly(N-(2-hydroxyethyl) methacryla-
mide)-oligolactates (pHEMAm-Lacn). The change in CP
over time is caused by the hydrolysis of the lactate side
group: as the polymer degrades and the lactate hydrolyzes,
the polymer becomes more hydrophilic, causing an increase
in the CP [134]. In both polymers, the initial CP is
dependent on the length of the lactate chain, and can
thus be tailored, though pHPMAm-Lac2 and pHEMAm-
Lac2 provide the most convenient CPs of 10◦C [136] and
22◦C [137], respectively. To create an amphiphilic block co-
polymer, PEG is most commonly used as the hydrophilic
segment to take advantage of its stealth properties and longer
circulation times [138], as previously described.
These micelles have encountered obstacles in preliminary
in vitro and in vivo experimentation, as release kinetics
of encapsulated paclitaxel have been in large part due to
diffusion rather than micelle destabilization [139]. In addi-
tion, fast degradation kinetics of the lactate chains, causing
quick micelle destabilization, resulted in no measurable
accumulation in mice 24 h after i.v. injection [140]. How-
ever, mPEG-b-p(HEMAm-Lacn) polymers modified with
methacryloxy-chloride in the micelle core have displayed
prolonged circulation times in vivo and increased tumor
accumulation compared to unmodified micelles [141]. This
new class of thermosensitive polymers shows promise for
future chemotherapy work.
2.3. Combined Smart Technologies. Because targeted particles
can increase uptake by endocytosis, pH-sensitive release is
desirable. Combining the benefits of a receptor-targeted
micelle and a pH-responsive drug conjugate was performed
by Bae et al. [92–95]. Targeting a surface receptor on cancer
cells can cause increased cellular uptake, and a pH-responsive
degradable bond between drug and polymer can cause
release in the low pH environment of the lysosome. Folate
was used as the targeting molecule and the pH-responsive
hydrazone bond was used to conjugate DOX to the polymer.
The self-assembling block copolymers required to prepare
the targeted and pH-responsive micelles (approximately 60
nm), consisted of folate-PEG-poly(aspartate hydrazone dox-
orubicin) [FOL-PEG-P(Asp-Hyd-DOX)]. Delivery to tumor
cells known to overexpress folate receptors has been shown
with micelles using folate as the targeting moiety to cause
increased endocytotic cellular uptake into the intracellular
acidic compartments known as endosomes (pH 5-6) [33].
Drugs conjugated within a micelle by a hydrazone linkage
show selective release within the low pH environment of
endosomes [76, 82, 89].
In terms of effective dose (ED), the effective doses for free
DOX and micelles without folate were similar, but the ED
for folate conjugated micelles was lowered 2-fold compared
to the free DOX micelles [93]. The overall findings by Bae
et al. suggest that an intracellular, environment-targeting
micelle drug carrier is one of the most effective approaches
for cancer treatment [92]. Liposomes with pH-sensitivity
and targeting ligands have also been effectively used to
increase residence time at the target cells, increase uptake,
and increase intracellular delivery [37, 96, 98].
3. Conclusion
Smart technologies in polymer nanomaterials offer a unique
way to deliver chemotherapy drugs to their intended target
without affecting healthy cells. By utilizing the naturally
low pH environment found in tumors and endosomes,
these drug carriers are free to circulate in the body, only
releasing their drugs at their intended location. Thermo-
sensitive polymer vehicles, when combined with localized
hyperthermia, can be triggered to release their payload at
the desired site. Ligands and aptamers, on the other hand,
provide a way for these vehicles to actively target cancerous
cells and then induce receptor-mediated endocytosis for
intracellular delivery. Compared to free drug and passive
nanomaterial systems, these smart devices have proven to
increase therapeutic effects and efficacy in a variety of cellular
and animal models. Progression of these techniques will
eventually lead to increased accuracy in delivering higher
doses and more toxic drugs, which will require challenges
like premature drug release and false cell targeting to be
addressed. As these technologies are further developed and
other methods of triggering and targeting emerge, smart
polymer nanomaterials will be able to provide improved
cancer treatment methods.
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